首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes
【24h】

A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes

机译:羟吡格吡酰型脂质化脂质体及其对抗PEG IgM诱导的影响及其加速脂质化脂质体的促进

获取原文
获取原文并翻译 | 示例
           

摘要

Surface decoration of liposomes with polyethylene glycol (PEG), PEGylation, is recognized as a method to bestow liposomes with a prolonged circulation time following intravenous administration. However, many reports have emphasized that a first dose of PEGylated liposomes (PL) elicits an anti-PEG IgM antibody response that can trigger a rapid systemic clearance of a second dose of PL via a phenomenon that is referred to as "accelerated blood clearance (ABC)." Such a phenomenon is usually observed with PL that has been modified with methoxy-PEG. In the current study, we introduced various functional groups, methoxy (OCH3), amino (NH2), carboxyl (COOH), and hydroxyl (OH), at the chain ends of PEG to investigate the effect on anti-PEG IgM induction. Among different PEG-modified liposomes, hydroxyl PEG-modified liposomes (PL-OH) efficiently attenuated the anti-PEG IgM response in vitro. In addition, PL-OH was less recognizable by anti-PEG IgM compared with other PLs. These findings raised the possibility that PL-OH could attenuate/abrogate elicitation of the ABC phenomenon. Nonetheless, upon repeated intravenous injection, PL-OH triggered the enhanced clearance of a subsequently injected second dose. Furthermore, in vitro studies have demonstrated that, as a complement activator, PL-OH is stronger than PL-OCH3 and induces further complement activation in the presence of anti-PEG IgM, which was the predominant contributor to the rapid clearance of a second dose of PL-OH. Our results suggest that the screening of complement activation by polymer-modified products in tandem with anti-polymer antibody production should be a prerequisite in the development of polymers that might enhance the therapeutic efficacy of nanocarriers.
机译:用聚乙二醇(PEG),聚乙二醇化的脂质体的表面装饰被认为是静脉内给药后延长循环时间赋予脂质体的方法。然而,许多报告强调,第一剂量的聚乙二醇化脂质体(PL)引发抗PEG IgM抗体响应,其可以通过称为“加速血液清除( ABC)。“通常用已用甲氧基-PEG改性的PL观察这种现象。在目前的研究中,我们介绍了各种官能团,甲氧基(OCH3),氨基(NH 2),羧基(COOH)和羟基(OH),以研究对抗PEG IgM诱导的影响。在不同的PEG改性脂质体中,羟基PEG改性脂质体(PL-OH)有效地减弱体外抗PEG IgM响应。另外,与其他PL相比,PL-OH不太识别。这些调查结果提出了PL-OH可以衰减/消除ABC现象的可能性。尽管如此,在重复静脉注射时,PL-OH引发了随后注射的第二剂量的增强的间隙。此外,在体外研究表明,作为补体激活剂,PL-OH较强比PL-OCH3更强,并且在抗PEG IgM存在下诱导进一步的补体激活,这是对第二剂量快速间隙的主要贡献者PL-OH。我们的研究结果表明,通过抗聚合物抗体产生的聚合物改性产物的补体激活筛选应成为可能增强纳米载体治疗效果的聚合物的先决条件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号